You need to be logged in to continue.

Please read the program information below and scroll to the bottom to continue to the course.

Seminar Overview

The goal of NAADAC's Life-Long Learning Series Innovations in Opioid Treatment: Buprenorphine is to bring together addiction professionals from many backgrounds to discuss medication-assisted treatment in a way that challenges ideas and perceptions and to present unbiased information that can be used to assess the best possible treatment for clients.

This educational program will discuss the four facets of opioid dependence and addiction (biological, psychological, social and spiritual), addiction as a disease and the scientific evidence to support this claim, three FDA-approved medications for opioid dependence, applying strategies to match clients to the most appropriate therapy, methods of motivating clients in opioid dependence treatment and building cooperative relationships between addiction professionals and prescribers.

Target Audience

NAADAC's Life-Long Learning Series Innovations in Opioid Treatment: Buprenorphine multi-level educational seminar is targeted at frontline clinicians who work in the addiction treatment and services profession. Addiction counselors, clinical supervisors, medical doctors, probation and parole officers, mental health and employee assistance professionals, teachers, researchers, social workers, psychologists, educators and government agency representatives will also benefit from the information presented during this educational seminar.

Educational Objectives

Participants of NAADAC's Life-Long Learning Series Innovations in Opioid Treatment: Buprenorphine will:

• Explore common misperceptions and biases regarding medication-assisted treatments for opioid dependence.
• Learn the psychopharmacology of opioid dependence.
• Recognize the differences between the three FDA-approved medication-assisted treatments for opioid dependence.
• Discuss the clinical aspects of medication management in the treatment setting, including: client selection, adherence issues, treatment planning and ongoing assessment.
• Discuss methods to overcome treatment obstacles and matching clients to the most appropriate therapy.
• Translate information presented during the educational seminar to clients, families and colleagues.

Seminar Agenda

Welcome and Introduction of Presenters
presented by Patricia Greer

Introduction to Opioids and Opioid Dependence
presented by Dr. Keith Crawford

Psychopharmacology of Opioids
presented by Dr. Keith Crawford

Opioid Dependence Treatment
presented by Dr. Keith Crawford

Counseling Buprenorphine Clients
presented by Cynthia Moreno Tuohy

Question and Answer Session
moderated by Cynthia Moreno Tuohy

Presenters

Keith Crawford, PhD, is a clinical pharmacist who conducts scientific research and clinical research in pharmacology. Dr. Crawford is also assistant professor in the Department of Pharmacology at Howard University College of Medicine and a visiting scientist at Johns Hopkins University School of Medicine, Department of Clinical Pharmacology. He has published research in pharmacology related to tumor biology, potentially novel treatments for cancer and potential treatments for HIV disease. He has been awarded patents for some of these innovations. He received a BS degree in Biology from Cornell University, a BS in Pharmacy from Temple University and a PhD in Pharmacology from the Uniformed Services University of the Health Sciences. He completed a residency in Clinical Pharmacy and a post-doctoral fellowship at the National Institutes of Health. Disclosures: Crawford currently serves on the Speaker's Bureau for Monogram Biosciences and GlaxoSmithKline concerning HIV/AIDS medications.

Cynthia Moreno Tuohy, NCAC II, CCDC III, SAP, is Executive Director of NAADAC, the Association for Addiction Professionals. She has recently served as the Executive Director of Danya Institute and the Central East Addiction Technology Transfer Center. Prior to this she was the Program Director for Volunteers of America Western Washington, serving homeless populations and dealing with the co-occurrence of poverty and substance abuse issues. In addition, she has been the administrator of multi-county, publicly funded alcohol/drug prevention/intervention/treatment centers with services ranging from prenatal care to the serving the elderly for over 20 years. Moreno Tuohy has developed partnerships with various national and international organizations to develop strategic plans, workforce development plans and educational curriculum. Disclosures: Moreno Tuohy does not have any financial or professional relationships with any pharmaceutical companies

Continuing Education Acceptance

Today's educational seminar, NAADAC's Life-Long Learning Series Innovations in Opioid Treatment: Buprenorphine, is approved for 1.5 continuing education (CE) contact hours by the following organizations:

• NAADAC, the Association for Addiction Professionals (NAADAC)
• National Association of Social Workers (NASW)
• National Board for Certified Counselors (NBCC)
• New York Office of Alcoholism and Substance Abuse Services (OASAS)
• Pardon, Probation & Parole Board
• Mental Health Consortium
• District of Columbia Certification Board (DCCB)/Professional Alcohol and other Drug Counselors (PADC)

Suggested Reading and Additional Resources

• Alcoholics Anonymous World Services, Inc. The AA Member – Medications & Other Drugs. [Brochure]. New York: Author, 1984.
  
• DiClemente, C.C. (2003). Addiction and change: How addictions develop and addicted people recover. New York: The Guilford Press.
  
• DiClemente, C.C., Schlundt, D., & Gemmell, L. (2004). Readiness and stages of change in addiction treatment. American Journal on Addictions, 13(2), 103-119.
  
• Goldstein, A. (2002). From biology to drug policy (2nd ed.). Boston: Oxford University Press.
  
• Koob, G.F., Sanna, P.P., & Bloom, F.E. (1998). Neuroscience of addiction. Neuron, 21, 467–476.
  
• Kosten, Thomas R., and Tony P. George. "The Neurobiology of Opioid Dependence: Implications for Treatment." Science and Practice Perspectives (July 2002): 13-21.
  
• Johnson, R.E., Chutuape, M.A., Strain, E.C., Walsh, S.L., Stitzer, M.L., and G.E. Bigelow (2000). "A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence." The New England Journal of Medicine, 343.18 (2000): 1290-1297.
  
• Johnson, R.E., Jaffe, J.H., and P.J. Fudala. "A Controlled Trial of Buprenorphine Treatment for Opioid Dependence." The Journal of the American Medical Association, 267.20 (1992): 2750-2754.
  
• Ling, W., Charuvastra, C., Collins, J.F., Batki, S., Brown, L.S., Kintaudi, P., et al. "Buprenorphine Maintenance Treatment of Opiate Dependence: A Multi-Center, Randomized Clinical Trial." Addiction, 93.4 (1998): 475-486.
  
• Messing, R.O. (2001). Biology of addiction. In E. Braunwald (Ed.), Harrison's principles of internal medicine (15th ed., Vol. 1) (pp.2557-2561). New York: McGraw-Hill.
  
• Miller, W.R. and S. Rollnick. Motivational Interviewing: Preparing People for Change. New York: Guilford Press, 2002.
  
• National Institute on Drug Abuse. (1999). Principles of drug addiction treatment: A research-based guide (NIH Publication No. 00-4180) [Brochure]. Rockville, MD: Department of Health and Human Services.
  
• National Institute on Drug Abuse. (2000). The brain: Understanding neurobiology through the study of addiction (NIH Publication No. 04-4871). Rockville, MD: Department of Health and Human Services.
  
• Prochaska, J. and DiClemente, C. (1984). The Transtheoretical approach: Crossing traditional boundaries of therapy. Homewood, IL: Dow Jones-Irwin.

Disclosures

Reckitt Benckiser Pharmaceuticals, Inc. awarded NAADAC, the Association for Addiction Professionals, an unrestricted educational grant to provide a multi-level educational seminar addressing medication-assisted treatments for opioid dependence.

NAADAC, the Association for Addiction Professionals, and its consultants were solely responsible for the course curriculum, development and creative design. Reckitt Benckiser Pharmaceuticals, Inc. did not contribute to or supervise this process.

Dr. Keith Crawford has received an honorarium from the unrestricted educational grant for his services today. However, Dr. Crawford is not affiliated with Reckitt Benckiser Pharmaceuticals, Inc. in any way.

NAADAC, the Association for Addiction Professionals, does not endorse the use of any particular treatment approach or medication-assisted treatment, irrespective of the specific mention of a specific treatment approach or medication during this educational seminar.

You need to be logged in to continue.